NZ609804A - Crystalline forms of an alkoxyimidazol-1-ylmethyl biphenyl carboxylic acid - Google Patents

Crystalline forms of an alkoxyimidazol-1-ylmethyl biphenyl carboxylic acid

Info

Publication number
NZ609804A
NZ609804A NZ609804A NZ60980411A NZ609804A NZ 609804 A NZ609804 A NZ 609804A NZ 609804 A NZ609804 A NZ 609804A NZ 60980411 A NZ60980411 A NZ 60980411A NZ 609804 A NZ609804 A NZ 609804A
Authority
NZ
New Zealand
Prior art keywords
carboxylic acid
crystalline forms
alkoxyimidazol
forms
biphenyl carboxylic
Prior art date
Application number
NZ609804A
Other languages
English (en)
Inventor
Paul R Fatheree
Venkat R Thalladi
Original Assignee
Theravance Biopharma R & D Ip Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Biopharma R & D Ip Llc filed Critical Theravance Biopharma R & D Ip Llc
Publication of NZ609804A publication Critical patent/NZ609804A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/70—One oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ609804A 2010-11-10 2011-11-09 Crystalline forms of an alkoxyimidazol-1-ylmethyl biphenyl carboxylic acid NZ609804A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41201110P 2010-11-10 2010-11-10
PCT/US2011/059895 WO2012064807A1 (en) 2010-11-10 2011-11-09 Crystalline forms of an alkoxyimidazol-1-ylmethyl biphenyl carboxylic acid

Publications (1)

Publication Number Publication Date
NZ609804A true NZ609804A (en) 2015-02-27

Family

ID=45003086

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ609804A NZ609804A (en) 2010-11-10 2011-11-09 Crystalline forms of an alkoxyimidazol-1-ylmethyl biphenyl carboxylic acid

Country Status (19)

Country Link
US (3) US8362060B2 (enExample)
EP (1) EP2638017B1 (enExample)
JP (2) JP2013542258A (enExample)
KR (1) KR20130130730A (enExample)
CN (1) CN103189362B (enExample)
AR (1) AR083828A1 (enExample)
AU (1) AU2011326622B2 (enExample)
BR (1) BR112013011715A2 (enExample)
CA (1) CA2812598A1 (enExample)
CO (1) CO6741224A2 (enExample)
ES (1) ES2567721T3 (enExample)
IL (1) IL225303A0 (enExample)
MX (1) MX2013005165A (enExample)
NZ (1) NZ609804A (enExample)
PH (1) PH12013500945A1 (enExample)
RU (1) RU2013126403A (enExample)
SG (1) SG189448A1 (enExample)
TW (1) TW201300366A (enExample)
WO (1) WO2012064807A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI448284B (zh) 2007-04-24 2014-08-11 Theravance Inc 雙效抗高血壓劑
CN106810542B (zh) * 2015-11-30 2021-03-09 苏州开拓药业股份有限公司 一种硫代咪唑烷酮化合物的晶型、盐型及其制备方法
CN117769540A (zh) * 2021-05-11 2024-03-26 亚士德制药公司 4-[5-[(3S)-3-氨基吡咯烷-l-羰基]-2-[2-氟-4-(2-羟基-2-乙基丙基)苯基]苯基]-2-氟-苯甲腈的盐的固体形式

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006027680A1 (en) 2004-09-10 2006-03-16 Pfizer Limited 3-(1-carbamoylcyclohexyl) propionic acid derivatives as inhibitors of neutral endopeptidase enzyme
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
WO2007106708A2 (en) 2006-03-10 2007-09-20 Novartis Ag Combinations of the angiotensin ii antagonist valsartan and the nep inhibitor daglutril
TWI448284B (zh) 2007-04-24 2014-08-11 Theravance Inc 雙效抗高血壓劑
TW201014830A (en) 2008-09-30 2010-04-16 Theravance Inc Crystalline form of an alkoxyimidazol-1-ylmethyl biphenyl carboxylic acid
TWI545114B (zh) * 2009-09-29 2016-08-11 施萬生物製藥研發Ｉｐ有限責任公司 製備聯苯基咪唑化合物之方法
US8399501B2 (en) 2010-03-04 2013-03-19 Theravance, Inc. Crystalline alkoxyimidazol-1-ylmethyl biphenyl carboxylic acid and methods for preparing thereof

Also Published As

Publication number Publication date
BR112013011715A2 (pt) 2017-10-31
US8802709B2 (en) 2014-08-12
JP2013542258A (ja) 2013-11-21
CO6741224A2 (es) 2013-08-30
EP2638017A1 (en) 2013-09-18
CN103189362B (zh) 2015-03-11
US8362060B2 (en) 2013-01-29
PH12013500945A1 (en) 2013-07-08
WO2012064807A1 (en) 2012-05-18
CN103189362A (zh) 2013-07-03
HK1187919A1 (zh) 2014-04-17
MX2013005165A (es) 2013-07-05
SG189448A1 (en) 2013-05-31
US20130267573A1 (en) 2013-10-10
KR20130130730A (ko) 2013-12-02
RU2013126403A (ru) 2014-12-20
TW201300366A (zh) 2013-01-01
AU2011326622A1 (en) 2013-04-04
ES2567721T3 (es) 2016-04-26
EP2638017B1 (en) 2016-01-27
IL225303A0 (en) 2013-06-27
AU2011326622B2 (en) 2014-12-18
CA2812598A1 (en) 2012-05-18
US20150133518A1 (en) 2015-05-14
JP2016028061A (ja) 2016-02-25
US9249105B2 (en) 2016-02-02
US20120115920A1 (en) 2012-05-10
AR083828A1 (es) 2013-03-27

Similar Documents

Publication Publication Date Title
PH12013500872A1 (en) Salt(s) of 7-cyclopentyl-2 -(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
EA201300669A1 (ru) Замещенные 1-бензилциклоалкилкарбоновые кислоты и их применение
NZ618734A (en) Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas
HK1202448A1 (en) Topical formulation for administering a compound
WO2012020131A3 (en) Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
PH12012500622A1 (en) Compounds for the treatment of dyslipidemia and related diseases
MX344238B (es) Compuestos de tetrazol y métodos para preparar y usar los mismos.
UA109868C2 (ru) Соединения n-алкилтриазола как антагонисты лизофосфатидной кислоты (lpar)
SG10201803862UA (en) Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
EP3626253A3 (en) Stable formulations of linaclotide
WO2012017166A3 (fr) Traitement d'une pathologie liee a un effet excessif du tnf par un compose de benzene sulfonamide
WO2015048662A3 (en) Substituted nicotinimide inhibitors of btk and their preparation and use in the treatment of cancer, inflammation and autoimmune disease
MX2011009709A (es) Compuestos para el tratamiento de la inflamacion y del dolor.
WO2012071369A3 (en) A non-retinoid rbp4 antagonist for treatment of age-related macular degeneration and stargardt disease
EA032951B1 (ru) Производное глутаримидов, его применение, фармацевтическая композиция на его основе, способ его получения
EP3228311A3 (en) Pharmaceutical and nutraceutical compositions of abscisic acid
WO2014140861A3 (en) Novel benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine as well as in cosmetics
UA96794C2 (ru) Глюкокортикоиды, способ их применения, способ лечения и фармацевтическая композиция на их основе
IN2013DN02555A (enExample)
PH12013500371A1 (en) Therapeutic agent for pain
MY150817A (en) Crystalline form of an alkoxyimidazol-1-ylmethyl biphenyl carboxylic acid
WO2012019428A8 (zh) 二苯甲醇类衍生物、其制备方法及其在医药上的应用
WO2012103282A3 (en) Methods and compositions for treating alzheimer's disease
MY182553A (en) Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: THERAVANCE BIOPHARMA R+D IP, LLC, US

Effective date: 20140807

PSEA Patent sealed
LAPS Patent lapsed